Terms: = Endocrine gland cancer AND CgA AND Prognosis
51 results:
1. [Adrenal cortical carcinoma in children: a clinicopathological analysis of 25 cases].
Wang RF; Guan WB; Li LX; Qiao M; Jiang RQ; Wang LF
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):40-45. PubMed ID: 38178745
[No Abstract] [Full Text] [Related]
2. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
3. Biomarkers in neuroendocrine neoplasms.
Zouli C; Zisimopoulou E; Chrisoulidou A
Hell J Nucl Med; 2023; 26 Suppl():44-48. PubMed ID: 37658563
[TBL] [Abstract] [Full Text] [Related]
4. A Clinicopathological and Molecular Analysis of Sellar/Suprasellar Neurocytoma Mimicking Pituitary Adenoma.
Zhang L; Fu W; Zheng L; Song F; Chen Y; Jiang C; Xing Z; Hu C; Ye Y; Zhang S; Yan X; Wang X
Front Endocrinol (Lausanne); 2022; 13():861540. PubMed ID: 35663322
[TBL] [Abstract] [Full Text] [Related]
5. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
[TBL] [Abstract] [Full Text] [Related]
6. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
Noor M; Huber AR; Cates JMM; Gonzalez RS
Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
[TBL] [Abstract] [Full Text] [Related]
7. Parathyroid carcinoma with sarcomatoid differentiation: a case report and literature review.
Hu L; Xie X
Diagn Pathol; 2020 Dec; 15(1):142. PubMed ID: 33317559
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm.
Shi H; Jiang C; Zhang Q; Qi C; Yao H; Lin R
Diagn Pathol; 2020 Sep; 15(1):108. PubMed ID: 32917216
[TBL] [Abstract] [Full Text] [Related]
9. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract] [Full Text] [Related]
10. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature.
Gaiani F; de'Angelis N; Minelli R; Kayali S; Carra MC; de'Angelis GL
Medicine (Baltimore); 2019 Sep; 98(37):e17154. PubMed ID: 31517859
[TBL] [Abstract] [Full Text] [Related]
11. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract] [Full Text] [Related]
12. [Primary carcinoid of ovary: a clinicopathologic analysis of 17 cases].
Zhu R; Xue XW; Luo YF; Wu HW; Huo Z
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):339-343. PubMed ID: 29783799
[No Abstract] [Full Text] [Related]
13. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity.
Rossi RE; Rausa E; Cavalcoli F; Conte D; Massironi S
Scand J Gastroenterol; 2018; 53(7):835-842. PubMed ID: 29726295
[TBL] [Abstract] [Full Text] [Related]
14. Metastatic neuroendocrine pancreatic tumor - Case report.
Radu EC; Saizu AI; Grigorescu RR; Croitoru AE; Gheorghe C
J Med Life; 2018; 11(1):57-61. PubMed ID: 29696066
[No Abstract] [Full Text] [Related]
15. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract] [Full Text] [Related]
16. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract] [Full Text] [Related]
17. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract] [Full Text] [Related]
18. Clinicopathological Features of Intraductal Pancreatic Neuroendocrine Tumors.
Chang XY; Jia CW; Meng YX; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):568-573. PubMed ID: 27825416
[TBL] [Abstract] [Full Text] [Related]
19. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
[TBL] [Abstract] [Full Text] [Related]
20. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.
Ito T; Hijioka S; Masui T; Kasajima A; Nakamoto Y; Kobayashi N; Komoto I; Hijioka M; Lee L; Igarashi H; Jensen RT; Imamura M
J Gastroenterol; 2017 Jan; 52(1):9-18. PubMed ID: 27539256
[TBL] [Abstract] [Full Text] [Related]
[Next]
